Today, the US FDA approved Erleada (apalutamide), an androgen receptor inhibitor created by Janssen Pharmaceuticals for the treatment of men with non-metastatic, castration-resistant prostate cancer. Erleada was approved after a priority review of...

This is a letter that we received from a recent helpline caller. It demonstrates the critical importance of support empowerment and information and how it prepares you for partnership with your medical professionals. This letter was published with permission from its author.